br Conclusion br This study confirmed the role of
This study confirmed the role of FABP-4 as an adipokine in pathogenesis of type 2 DM, breast cancer & diabetic subjects with breast cancer via enhancing angiogenesis (increased serum VEGF), inflammatory biomarkers (increased serum TNF-a) and oxidative stress (increased serum 8-OHdG & decreased serum ThxR activity). This can gives strong guidelines in management of type 2 DM, breast cancer & diabetic subjects with breast cancer by anti-FABP-4 therapy.
Conflicts of interest
This study confirmed the role of FABP-4 in pathogenesis of type 2 diabetes & breast cancer.
The role of FABP-4 via enhancing angiogenesis, inflammatory and epigenetic instability biomarkers.
This study evaluated the effect of some adipocytokines, in-flammatory, epigenetic instability & angiogenesis biomarkers in type 2 diabetic Egyptian women with breast cancer.
Appendix A. Supplementary data
 Ertunc M, Hotamisligil G. Lipid signaling and lipotoxicity in metabolic inflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res 2016;57(12):2099e114.  Niu G, Li J, Wang H, et al. Associations of A-FABP with anthropometric and metabolic indices and inflammatory cytokines in obese patients with newly diagnosed type 2 diabetes. BioMed Res Int 2016;2016, 9382092.
 Furuhashi M, Fucho R, Gorgün€ C, et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008;118:2640e50.  Hotamisligil G, Bernlohr D. Metabolic functions of FABPs-mechanisms and therapeutic implications. Nat Rev Endocrinol 2015;11:592e605.  Kim V, Lee Y, Koo J. Differential Trizma maleate of lipid metabolism-related pro-teins in different breast cancer subtypes. PLoS One 2015;10(3), e0119473.  Brownlee M. The pathobiology of diabetic complications: a unifying mecha-nism. Diabetes 2005;54:1615e25.  Xu G, Yao Q, Weng Q, et al. Study of urinary 8-hydroxydeoxyguanosine as a
biomarker of oxidative DNA damage in diabetic nephropathy patients.
 Lim H, Blann A, Chong A, et al. Plasma vascular endothelial growth factor,
Angiopoietin-1, and Angiopoietin-2 in diabetes implications for cardiovascu-lar risk and effects of multifactorial intervention. Diabetes Care 2004;27: 2918e24.
 Peng X, Gimenez-Cassina A, Petrus P, et al. Thioredoxin reductase 1 sup-presses adipocyte differentiation and insulin responsiveness. Sci Rep 2016;6: 28080.
 Dong C, Zhang L, Sun R, et al. Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress. Sci Rep 2016;6:36860.  American Diabetes Association. Diagnosis and classification of diabetes mel-litus. Diabetes Care 2013;36(1):67e74.  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;91:403e10.
 Fossati P, Prencipe L. Serum triglycerides determined colometrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077e80.  Gordon T, Zidek W, Amer M. Determination of high density lipoprotein cholesterol. J Med 1977;42:707e10.  Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ul-tracentrifuge. Clin Chem 1972;18:499e502.
 Merdad A, Karim S, Schulten HJ, et al. Transcriptomics profiling study of breast cancer from Kingdom of Saudi Arabia revealed altered expression of Adipo-nectin and Fatty Acid Binding Protein 4: is lipid metabolism associated with breast cancer? BMC Genom 2015;16(1):S11.
 Lamoke F, Bartoli M. Decreased thioredoxin reductase activity in endothelial cells exposed to high glucose is associated with protein tyrosine nitration and interaction with caveolin 1. Faseb J 2013;27(1). Supplement1183:7.  Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999;20(9):1657e66.
 Murakami T. Kallikrein-kinin system: an emerging competitor or collaborator for VEGF in diabetic macular edema? Diabetes 2015;64:3350e2.  Bolinger MT, Antonetti DA. Moving past anti-VEGF: novel therapies for treating diabetic retinopathy. Int J Mol Sci 2016;17:1498e521.  Liu L, Tong Q, Liu S, et al. ZEB1 upregulates VEGF expression and stimulates angiogenesis in breast cancer. PLoS One 2016;11(2), e0148774.  Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, et al. High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer. Mol Clin Oncol 2015;3:1103e8.
 Furuhashi M, Saitoh S, Shimamoto K, et al. Fatty Acid-Binding Protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of meta-bolic and cardiovascular diseases. Clin Med Insights Cardiol 2014;8:23e33.